Solventum Corporation

Solventum Corporation (NYSE: SOLV) is a publicly traded American healthcare company headquartered in Eagan, Minnesota. Incorporated on January 24, 2023, it was officially spun off from 3M Company on April 1, 2024, to operate as an independent entity. As of May 2026, Solventum has approximately 20,000 to 22,000 employees, with a trailing twelve-month revenue of approximately $8.2 billion and a market capitalization of about $12.9 billion.

The company develops, manufactures, and commercializes a broad portfolio of healthcare solutions globally. Solventum operates primarily through three segments: MedSurg, Dental Solutions, and Health Information Systems. The MedSurg segment includes offerings such as negative pressure wound therapy, advanced wound dressings, surgical supplies, and stethoscopes. Its Dental Solutions segment provides products like brackets, aligners, and restorative materials, while Health Information Systems offers software solutions for computer-assisted physician documentation, coding automation, and speech recognition. Solventum previously had a Purification & Filtration business, which was sold to Thermo Fisher Scientific in February 2025.

Solventum is an active participant in patent litigation, appearing as both a plaintiff and a defendant in tracked cases. The company has one tracked case as a plaintiff and one as a defendant, indicating a two-way litigation posture common for operating companies defending their intellectual property and asserting it when necessary. These cases are venued in the PTAB and the Texas Western District Court.

A notable context for Solventum's litigation includes its recent spin-off from 3M. The tracked cases involve "Wound Healing Technologies, LLC" where Solventum is both the plaintiff in a PTAB action (2025-06-13) and the defendant in a Texas Western District Court case (2024-11-15). This suggests patent disputes directly related to Solventum's key MedSurg offerings, particularly in advanced wound care.